Trends in advanced glycation end products research in diabetes mellitus and its complications

Molecular and Cellular Biochemistry

Volumn 341, Issue 1-2, 2010, Pages 33-41

  Méndez, José D ^a,b   Xie, Jianling ^c   Aguilar Hernández, Montserrat ^c   Méndez Valenzuela, Verna ^d  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Advanced glycation end products; Diabetes mellitus; Diabetic complications; Hyperglycemia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; AMINOSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ARGININE; CADAVERINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PUTRESCINE; PYRIDORIN; PYRIDOXAMINE; SPERMIDINE; SPERMINE; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANALYTIC METHOD; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL DAMAGE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ERECTILE DYSFUNCTION; GLOMERULOSCLEROSIS; HUMAN; IMMUNOLOGICAL TECHNIQUE; MESANGIUM CELL; NONHUMAN; PROTEIN METABOLISM; QUANTITATIVE ANALYSIS; RETINOPATHY; REVIEW;

DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RESEARCH;

EID: 77955013031     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-010-0434-5     Document Type: Review

References (82)

1. H Kusunoki S Miyata T Ohara, et al. 2003 Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy Diabetes Care 26 1889 1894 10.2337/diacare.26.6.1889 1:CAS:528:DC%2BD3sXkslKrtb0%3D 12766129 (Pubitemid 36929139)
2. IL Chaikoff GS Lachman 1933 Occurrence of cataracts in experimental pancreatic diabetes Proc Soc Exp Biol Med 31 237 241
3. Colaco C (1997) Glycation and advanced glycation endproducts. In: The glycation hypothesis of atherosclerosis. Chapman & Hall, Austin, pp 57-61
4. G Ronca R Chiti A Lucacchini 1970 Separation of epsilon-carboxymethyl- lysine from methionine on 60-cm columns of ion-exchange resins J Chromatogr 47 114 115 10.1016/0021-9673(70)80016-4 1:CAS:528:DyaE3cXhtVKrtL0%3D 5418115
5. T Nakayama F Hayase H Kato 1980 Formation of e-(2-formyl-5-hydroxy- methyl-pyrrol-1-yl)-l-norleucine in the Maillard Reaction between d-glucose and l-lysine Agric Biol Chem 44 1201 1202 1:CAS:528:DyaL3cXkvFGltrY%3D
6. G Njore A Fernandes VM Monnier 1998 Mechanism of formation of putative advanced glycosylation and product and protein cross-link 2-(2-furoyl)-4(5)-(2- furanyl)-1H-imidazolone J Biol Chem 263 10646 10652
7. K Biemel O Reihl J Conrad, et al. 2001 Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor J Biol Chem 276 23405 23412 10.1074/jbc.M102035200 1:CAS:528:DC%2BD3MXltVWjsb4%3D 11279247
8. K Nakamura Y Nakazawa K Ienaga 1997 Acid-stable fluorescent advanced glycation end products: vesperlysine A, B and C are formed as crosslinked products in the Maillard reaction between lysine or proteins with glucose Biochem Biophys Res Commun 232 227 230 10.1006/bbrc.1997.6262 1:CAS:528:DyaK2sXhvVyltbg%3D 9125137 (Pubitemid 27211953)
9. K Biemel D Friedl M Lederer 2002 Identification and quantification of major Maillard cross-links in human serum albumin and lens protein. Evidence for glucosepane as the dominant compound J Biol Chem 277 24907 24915 10.1074/jbc.M202681200 1:CAS:528:DC%2BD38XlsVWit78%3D 11978796 (Pubitemid 34951792)
10. K Horie T Miyata T Yasuda, et al. 1997 Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons Biochem Biophys Res Commun 236 327 332 10.1006/bbrc.1997.6944 1:CAS:528:DyaK2sXkvVWnsb8%3D 9240434 (Pubitemid 27373293)
11. J Rietbrock 2004 Advanced glycation end-products and the progress of diabetic vascular complications Physiol Res 53 131 142 15046548
12. ME Cooper 2004 Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease Am J Hypertens 17 31S 38S 10.1016/j.amjhyper.2004.08.021 1:CAS:528:DC%2BD2cXhtVyqsrjM 15607433 (Pubitemid 39647569)
13. M Brownlee 2001 Biochemistry and molecular cell biology of diabetic complications Nature 414 813 820 10.1038/414813a 1:CAS:528: DC%2BD38Xhtlyltg%3D%3D 11742414 (Pubitemid 34000785)
14. AM Schmidt SD Yan SF Yan, et al. 2000 The biology of the receptor for advanced glycation end products and its ligands Biochim Biophys Acta 1498 99 111 10.1016/S0167-4889(00)00087-2 1:CAS:528:DC%2BD3cXosFCjsrw%3D 11108954
15. CH Yeh L Sturgis J Haidacher, et al. 2001 Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion Diabetes 50 1495 1504 10.2337/diabetes.50.6.1495 1:CAS:528:DC%2BD3MXkvFSgt78%3D 11375353
16. S Schwedler R Schinzel P Vaith, et al. 2001 Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 59 S32 S36 10.1046/j.1523-1755.2001.07839.x
17. L Lin S Park EG Lakatta 2009 RAGE signaling in inflammation and arterial aging Front Biosci 14 1403 1413 10.2741/3315 1:CAS:528:DC%2BD1MXltFejurc%3D 19273137
18. H Vlassara M Brownlee K Manogue, et al. 1988 Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling Science 240 1546 1548 10.1126/science.3259727 1:CAS:528:DyaL1cXktlKgtLs%3D 3259727
19. Y Zhang JX Lin J Vilcek 1990 Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence Mol Cell Biol 10 3818 3823 1:CAS:528:DyaK3cXlt1Ontbw%3D 2192263
20. M Brownlee A Cerami H Vlassara 1988 Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications N Engl J Med 318 1315 1320 1:STN:280:DyaL1c3gt1SksA%3D%3D 3283558
21. T Soulis V Thallas S Youssef, et al. 1997 Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury Diabetologia 40 619 628 10.1007/s001250050725 1:CAS:528:DyaK2sXkt1yqurY%3D 9222639 (Pubitemid 27288105)
22. N Tanaka H Yonekura S Yamagishi, et al. 2000 The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor through nuclear factor-κB, and by 17beta-estradiol through Sp1 in human vascular endothelial cells J Biol Chem 275 25781 25790 10.1074/jbc.M001235200 1:CAS:528:DC%2BD3cXmtVehtL4%3D 10829018
23. G Barile S Pachydaki SR Tari, et al. 2005 The RAGE axis in early diabetic retinopathy Invest Ophthalmol 46 2916 2924 10.1167/iovs.04-1409 (Pubitemid 43086714)
24. YM Li T Mitsuhashi D Wojciechowicz, et al. 1996 Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins Proc Natl Acad Sci USA 93 11047 11052 10.1073/pnas.93.20.11047 1:CAS:528:DyaK28XmtVOku7g%3D 8855306 (Pubitemid 26333115)
25. A Miyazaki H Nakamura S Horiuchi 2002 Scavenger receptors that recognize advanced glycation end products Trends Cardiovasc Med 12 258 262 10.1016/S1050-1738(02)00171-8 1:CAS:528:DC%2BD38XntVaqsb0%3D 12242049 (Pubitemid 35286763)
26. N Ohgami R Nagai M Ikemoto, et al. 2002 CD36 serves as a receptor for AGEs J Diabetes Complicat 16 56 59 10.1016/S1056-8727(01)00208-2 11872368 (Pubitemid 34168502)
27. A Bierhaus PM Humpert M Morcos, et al. 2005 Understanding RAGE, the receptor for advanced glycation end products J Mol Med 83 876 886 10.1007/s00109-005-0688-7 1:CAS:528:DC%2BD2MXht1SksbjP 16133426 (Pubitemid 41598688)
28. P Mene F Festuccia F Pugliese 2003 Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus Am J Cardiovasc Drugs 3 315 320 10.2165/00129784-200303050-00002 1:CAS:528:DC%2BD3sXpsVSqurc%3D 14728065 (Pubitemid 37369364)
29. N Giannoukakis 2005 Pyridoxamine (BioStratum) Curr Opin Investig Drugs 6 410 418 1:CAS:528:DC%2BD2MXktF2gsbo%3D 15898348
30. RG Khalifah JW Baynes BG Hudson 1999 Amadorins: novel post-Amadori inhibitors of advanced glycation reactions Biochem Biophys Res Commun 257 251 258 10.1006/bbrc.1999.0371 1:CAS:528:DyaK1MXit1yksr8%3D 10198198 (Pubitemid 29301430)
31. PV Vaitkevicius M Lane H Spurgeon, et al. 2001 A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys Proc Natl Acad Sci USA 98 1171 1175 10.1073/pnas.98.3.1171 1:CAS:528: DC%2BD3MXht1SmtrY%3D 11158613 (Pubitemid 32121205)
32. BH Wolffenbuttel CM Boulanger FR Crijns MS Huijberts P Poitevin GN Swennen, et al. 1998 Breakers of advanced glycation end products restore large artery properties in experimental diabetes Proc Natl Acad Sci USA 95 4630 4634 10.1073/pnas.95.8.4630 1:CAS:528:DyaK1cXis1Ogsb0%3D 9539789 (Pubitemid 28207964)
33. DA Kass EP Shapiro M Kawaguchi, et al. 2001 Improved arterial compliance by a novel advanced glycation end-product crosslink breaker Circulation 104 1464 1470 10.1161/hc3801.097806 1:CAS:528:DC%2BD3MXnvVeqtLY%3D 11571237
34. Q Dan R Wong SK Chung, et al. 2004 Interaction between the polyol pathway and non-enzymatic glycation on aortic smooth muscle cell migration and monocyte adhesion Life Sci 76 445 459 10.1016/j.lfs.2004.09.010 1:CAS:528: DC%2BD2cXpsFWqs70%3D 15530506 (Pubitemid 39458312)
35. A Beyer-Mears K Mistry FP Diecke, et al. 1996 Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus Pharmacology 52 292 302 10.1159/000139394 1:CAS:528:DyaK28XjvVGlsbw%3D 8807673
36. S Yamagishi T Matsui K Nakamura, et al. 2005 Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation Int J Tissue React 27 189 195 1:CAS:528:DC%2BD28XjtlWktr8%3D 16440584
37. Y Duraisamy J Gaffney M Slevin, et al. 2003 Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine Mol Cell Biochem 246 143 153 10.1023/A:1023470921116 1:CAS:528:DC%2BD3sXjtFKmsbs%3D 12841356 (Pubitemid 36798735)
38. JD Méndez LI Leal 2004 Inhibition of in vitro pyrraline formation by l-arginine and polyamines Biomed Pharmacother 58 598 604 10.1016/j.biopha. 2004.09.004 15589069 (Pubitemid 40260383)
39. JD Méndez J Xie E García-Pérez 2007 Urea inhibits the in vitro formation of fluorescent advanced glycation end products World Appl Sci J 2 90 98
40. MC Thomas JW Baynes SR Thorpe, et al. 2005 The role of AGEs and AGE inhibitors in diabetic cardiovascular disease Curr Drug Targets 6 453 474 10.2174/1389450054021873 1:CAS:528:DC%2BD2MXlslChtb4%3D 16026265 (Pubitemid 40916272)
41. M Ruiz-Ortega O Lorenzo M Ruperez, et al. 2000 ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect Nephrol Dial Transpl 15 561 565 10.1093/ndt/15.5.561 1:CAS:528:DC%2BD3cXktVKktr0%3D
42. G Wolf EG Neilson 1993 Angiotensin II as a renal growth factor J Am Soc Nephrol 3 1531 1540 1:CAS:528:DyaK3sXkvVKjurY%3D 8507808
43. BM Brenner ME Cooper D de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D 11565518
44. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259
45. JM Forbes ME Cooper V Thallas, et al. 2002 Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy Diabetes 51 3274 3282 10.2337/diabetes.51.11.3274 1:CAS:528:DC%2BD38Xos1ahtLc%3D 12401719
46. A Goldin JA Beckman AM Schmidt, et al. 2006 Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 597 605 10.1161/CIRCULATIONAHA.106.621854 1:CAS:528:DC%2BD28Xns1Snu70%3D 16894049 (Pubitemid 44199649)
47. S Yamagishi K Nakamura T Matsui, et al. 2006 Cardiovascular disease in diabetes Mini-Rev Org Chem 6 313 318 1:CAS:528:DC%2BD28XislSmsL8%3D
48. M Kaneko L Bucciarelli YC Hwang, et al. 2005 Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury Ann N Y Acad Sci 1043 702 719 10.1196/annals.1333.081 1:CAS:528:DC%2BD2MXpvVKqurg%3D 16037296 (Pubitemid 41123963)
49. S Yamagishi Y Inagaki T Okamoto, et al. 2002 Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells J Biol Chem 277 20309 20315 10.1074/jbc.M202634200 1:CAS:528: DC%2BD38XkslWgtrs%3D 11912219 (Pubitemid 34967325)
50. LD Dworkin I Ichikawa BM Brenner, et al. 1983 Hormonal modulation of glomerular function Am J Physiol 244 F95 F104 1:CAS:528:DyaL3sXmsFGrtg%3D%3D 6297313
51. S Silbiger S Crowley Z Shan, et al. 1993 Nonenzymatic elevated glucose reduces collagen synthesis and proteoglycan charge Kidney Int 43 853 864 10.1038/ki.1993.120 1:CAS:528:DyaK3sXltFCksb4%3D 8479121
52. M Brownlee 1994 Glycation and diabetic complications Diabetes 43 836 841 1:CAS:528:DyaK2cXltVGhu7w%3D 8194672
53. Yamagishi S, Takeuchi M, Makita Z (2001) Advanced glycation end products and the pathogenesis of diabetic nephropathy. In: Tomino Y (ed) Type-2 diabetic nephropathy in Japan. From bench to bedside. Contrib Nephrol 134:30-35
54. S Yamagishi Y Inagaki T Okamoto, et al. 2003 Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells Kidney Int 63 464 473 10.1046/j.1523-1755.2003.00752.x 1:CAS:528:DC%2BD3sXht1yrs7c%3D 12631112 (Pubitemid 36126793)
55. K Sharma FN Ziyadeh 1995 Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator Diabetes 44 1139 1146 10.2337/diabetes.44.10.1139 1:CAS:528:DyaK2MXotlGhu74%3D 7556948
56. DG Cogan D Toussaint T Kuwabara 1961 Retinal vascular patterns. IV. Diabetic retinopathy Arch Ophthalmo 66 366 378 1:STN:280:DyaF3c%2FhtlKgug%3D%3D
57. LJ Mandarino 1992 Current hypotheses for the biochemical basis of diabetic retinopathy Diabetes Care 15 1892 1901 10.2337/diacare.15.12.1892 1:STN:280:DyaK3s%2FpvFOksQ%3D%3D 1464244
58. RN Frank 1990 On the pathogenesis of diabetic retinopathy. A 1990 update Ophthalmology 98 586 593
59. IM Herman PA D'Amore 1985 Microvascular pericytes contain muscle and nonmuscle actins J Cell Biol 101 43 52 10.1083/jcb.101.1.43 1:CAS:528: DyaL2MXks1ylur0%3D 3891763 (Pubitemid 15061252)
60. NC Joyce MF Haire GE Palade 1985 Contractile proteins in pericytes. II. Immunocytochemical evidence for the presence of two isomyosins in graded concentrations J Cell Biol 100 1387 1395 10.1083/jcb.100.5.1387 1:CAS:528:DyaL2MXitFyrsbs%3D 3886666 (Pubitemid 15098013)
61. S Yamagishi CC Hsu M Taniguchi, et al. 1995 Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy Biochem Biophys Res Commun 213 681 687 10.1006/bbrc.1995.2185 1:CAS:528:DyaK2MXnsFKiuro%3D 7646524
62. S Yamagishi S Amano Y Inagaki, et al. 2002 Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes Biochem Biophys Res Commun 290 973 978 10.1006/bbrc.2001.6312 1:CAS:528:DC%2BD38XksV2juw%3D%3D 11798169 (Pubitemid 34687457)
63. CR Moore R Wang 2006 Pathophysiology and treatment of diabetic erectile dysfunction Asian J Androl 8 675 684 10.1111/j.1745-7262.2006.00223.x 16892168 (Pubitemid 44869615)
64. KE Andersson G Wagner 1995 Physiology of penile erection Physiol Rev 75 191 236 1:CAS:528:DyaK2MXjvVOguro%3D 7831397
65. F Giuliano O Rampin 2000 Central control of erection and its pharmacological modification Curr Opin Urol 10 629 633 10.1097/00042307- 200011000-00017 1:STN:280:DC%2BD3M7nsFyqsQ%3D%3D 11148738
66. MR Melis A Argiolas 1997 Role of central nitric oxide in the control of penile erection and yawning Prog Neuro-Psychopharmacol Biol Psychiatry 21 899 922 10.1016/S0278-5846(97)00088-2 1:CAS:528:DyaK2sXmtVGjsLc%3D (Pubitemid 27410384)
67. DR Sell VM Monnier 1989 Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process J Biol Chem 264 21597 21602 1:CAS:528:DyaK3cXjtlygsg%3D%3D 2513322
68. RH Nagaraj IN Shipanova FM Faust 1996 Protein cross-linking by the Maillard reaction J Biol Chem 271 19338 19345 10.1074/jbc.271.32.19338 1:CAS:528:DyaK28XkvFymsrk%3D 8702619 (Pubitemid 26271604)
69. M Kalousova T Zima IM Malbohan, et al. 2002 Determination of advanced glycation end products Sb Lek 103 427 434 1:CAS:528:DC%2BD3sXjtVOmtL0%3D 12688155
70. S Amanoa Y Kajia T Oshikaa, et al. 2001 Advanced glycation end products in human optic nerve head Br J Ophthalmol 85 52 55 10.1136/bjo.85.1.52 (Pubitemid 32060195)
71. N Sasaki R Fukatsu K Tsuzuki, et al. 1998 Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases Am J Pathol 153 1149 1155 1:CAS:528:DyaK1cXmvFGmsbc%3D 9777946
72. R Petrovic J Futas J Chandoga, et al. 2005 Rapid and simple method for determination of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl) lysine in urine using gas chromatography/mass spectrometry Biomed Chromatogr 19 649 654 10.1002/bmc.491 1:CAS:528:DC%2BD2MXht1KgurzO 15803449 (Pubitemid 41723115)
73. N Ahmed R Babaei-Jadidi SK Howell, et al. 2005 Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes Diabetologia 48 1590 1603 10.1007/s00125-005-1810-7 1:CAS:528:DC%2BD2MXnslyrt7k%3D 15988580 (Pubitemid 41175513)
74. PJ Thornalley 2005 Measurement of protein glycation, glycated peptides, and glycation free adducts Perit Dial Int 25 522 533 1:CAS:528: DC%2BD28Xks1eluw%3D%3D 16419322
75. T Kislinger A Humeny CC Peich, et al. 2005 Analysis of protein glycation products by MALDI-TOF/MS Ann N Y Acad Sci 1043 249 259 10.1196/annals.1333.030 1:CAS:528:DC%2BD2MXpvVKqsbs%3D 16037245 (Pubitemid 41123912)
76. S Shimada Y Tanaka C Ohmura, et al. 2005 N-(carboxymethyl)valine residues in hemoglobin (CMV-Hb) reflect accumulation of oxidative stress in diabetic patients Diabetes Res Clin Pract 69 272 278 10.1016/j.diabres.2005.01.007 1:CAS:528:DC%2BD2MXns1Squr0%3D 16098924 (Pubitemid 41140107)
77. CG Schalkwijk PM Wee CD Stehouwer 2005 Plasma levels of AGE peptides in type 1 diabetic patients are associated with serum creatinine and not with albumin excretion rate:Possible role of AGE peptide-associated endothelial dysfunction Ann N Y Acad Sci 1043 662 670 10.1196/annals.1333.075 1:CAS:528:DC%2BD2MXpvVKqur4%3D 16037290 (Pubitemid 41123957)
78. R Nagai EK Deemer JW Brock, et al. 2005 Effect of glucose concentration on formation of AGEs in erythrocytes in vitro Ann N Y Acad Sci 1043 146 150 10.1196/annals.1333.018 1:CAS:528:DC%2BD2MXpvVKqsL0%3D 16037233 (Pubitemid 41123900)
79. S Yamagishi K Nakamura H Inoue, et al. 2005 Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease Med Hypotheses 64 1205 1207 10.1016/j.mehy.2005.01.016 1:CAS:528:DC%2BD2MXjtVyrsb0%3D 15823718
80. CJ Konings CG Schalkwijk FM van der Sande, et al. 2005 Influence of icodextrin on plasma and dialysate levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine Perit Dial Int 25 591 595 1:CAS:528:DC%2BD28Xks1ektg%3D%3D 16411527
81. M Peppa H Brem W Cai, et al. 2006 Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711) Am J Nephrol 26 430 436 10.1159/000095786 1:CAS:528:DC%2BD28XhtlWnur%2FP 16974073 (Pubitemid 44971733)
82. HF Bunn KH Gabbay PM Gallop 1978 The glycosylation of hemoglobin: relevance to diabetes mellitus Science 200 21 27 10.1126/science.635569 1:CAS:528:DyaE1cXhvVOht7w%3D 635569